COVID-19 vaccination in our transplant recipients: The time is now

JOURNAL OF HEART AND LUNG TRANSPLANTATION

卷:40

Article

Aslam, Saima¹  Goldstein, Daniel R.^2,3  Vos, Robin^4,5  Gelman, Andrew E.⁶  Kittleson, Michelle M.⁷  Wolfe, Cameron⁸  Danziger-Isakov, Lara⁹ 

[1] Univ Calif San Diego, Dept Med, Div Infect Dis & Global Publ Hlth, San Diego, CA 92121 USA

[2] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA

[3] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA

[4] Univ Hosp Leuven, Dept Resp Dis, Leuven, Belgium

[5] Katholieke Univ Leuven, Lung Transplant Unit, Lab Resp Dis & Thorac Surg Breathe, Dept Chron Dis & Metab, Leuven, Belgium

[6] Washington Univ, Sch Med St Louis, Dept Surg, St Louis, MO 63110 USA

[7] Cedars Sinai, Dept Cardiol, Smidt Heart Inst, Los Angeles, CA USA

[8] Duke Univ, Dept Med, Div Infect Dis, Durham, NC USA

[9] Univ Cincinnati, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA

关键词: SARS-CoV-2;    COVID-19;    vaccine;    transplant;    pandemic;    vaccination;   

DOI  :  10.1016/j.healun.2020.12.009

来源: Elsevier

【 摘 要 】

We are entering 2021 with an expanding and effective COVID-19 vaccine armamentarium. Recent interim results from COVID-19 vaccine trials, including more than 80,000 participants worldwide, demonstrate remarkable efficacy and low rate of serious adverse events. Based on experience with other vaccines in transplant recipients and knowing the risk of severe COVID-19 in this population, we believe that COVID-19 vaccines provide potential benefit with minimal risk. We strongly support and encourage COVID-19 vaccination of our transplant recipients. (C) 2021 International Society for Heart and Lung Transplantation. All rights reserved.

【 授权许可】

Free